Contemporary open ureteral reimplantation without morphine: assessment of pain and outcomes.
Karim Chamie, Andrew Chi, Brian Hu...
https://pubmed.ncbi.nlm.nih.gov/19625056/Actively Recruiting
Led by University of California, Davis · Updated on 2026-01-29
100
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating whether transdermal oxybutynin is better than oral oxybutynin at reducing bladder pain and urgency after bladder surgery in children aged 4 to 8 years. Bladder pain and urgency are common after surgery, and current treatments include narcotics, anti-inflammatory drugs, and oral oxybutynin, which has limited effectiveness due to how the body processes it. This study focuses on comparing these two delivery methods to find the best way to manage pain and urgency after surgery.
CONDITIONS
Oxybutynin for Post-surgical Bladder Pain and Urgency
A
Anjali Vij, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, Davis
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Oxybutynin Transdermal Patch | Oral Oxybutynin |
|---|---|---|
| What it is | A skin patch that delivers oxybutynin throughout the day for bladder symptom control after surgery. | Tablets of oxybutynin taken every 8 hours to manage bladder urgency and pain after surgery. |
| Role in trial | Evaluated as an alternative administration method to oral oxybutynin for pediatric patients following bladder surgery. | Serves as the standard active comparator, reflecting usual clinical practice for managing bladder symptoms in this setting. |
| Primary use | Reduces urgency and pain from an overactive bladder after surgery by delivering oxybutynin continuously through the skin. | Controls bladder urgency and pain using oral doses of oxybutynin, which is broadly used for these symptoms after surgery. |
| How it is given or performed | A patch is applied to the skin and releases medication over 3 to 4 days; requires periodic replacement, avoiding the need for tablets. | Tablets are given every 8 hours during hospitalization; timing and dosing are managed by the clinical team. |
| Evidence status | Published studies support its effectiveness and tolerability for overactive bladder symptoms in children, though specific safety data after bladder surgery is still being established. | A large body of evidence supports oral oxybutynin for pediatric bladder symptom control, including direct comparisons to the patch for efficacy and safety. |
| Important limitations | The patch may cause skin irritation or difficulty with adherence, and requires periodic changes. There is less published safety data for its use immediately after bladder surgery than for chronic therapy. | Oral oxybutynin can cause dry mouth, constipation, and may interact with other medications. Some children may not tolerate frequent dosing or experience central nervous system effects. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From the day prior to surgery through hospital stay (approximately 1 week)
Participants receive oxybutynin either as a transdermal patch applied the day prior to surgery or as oral medication starting preoperatively and continued every 8 hours postoperatively while in the hospital.
1 preoperative visit and daily hospital visits during treatment
Duration - Up to 6 weeks postoperatively
Participants are monitored for pain, urgency, and narcotic usage after surgery for up to six weeks.
Weekly visits for up to 6 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Karim Chamie, Andrew Chi, Brian Hu...
https://pubmed.ncbi.nlm.nih.gov/19625056/Joseph M Gleason, Catherine Daniels, Katharine Williams...
https://pubmed.ncbi.nlm.nih.gov/24477421/Patrick C Cartwright, Douglas E Coplen, Barry A Kogan...
https://pubmed.ncbi.nlm.nih.gov/19683731/Eric A Kurzrock, Yvonne Y Chan, Blythe P Durbin-Johnson...
https://pubmed.ncbi.nlm.nih.gov/30266334/University of California, Davis
Lead Sponsor